Literature DB >> 19914445

Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Drucy Borowitz, Karen A Robinson, Margaret Rosenfeld, Stephanie D Davis, Kathryn A Sabadosa, Stephanie L Spear, Suzanne H Michel, Richard B Parad, Terry B White, Philip M Farrell, Bruce C Marshall, Frank J Accurso.   

Abstract

Newborn screening for cystic fibrosis (CF) offers the opportunity for early medical and nutritional intervention that can lead to improved outcomes. Management of the asymptomatic infant diagnosed with CF through newborn screening, prenatal diagnosis, or sibling screening is different from treatment of the symptomatically diagnosed individual. The focus of management is on maintaining health by preventing nutritional and respiratory complications. The CF Foundation convened a committee to develop recommendations based on a systematic review of the evidence and expert opinion. These guidelines encompass monitoring and treatment recommendations for infants diagnosed with CF and are intended to help guide families, primary care providers, and specialty care centers in the care of infants with CF.

Entities:  

Mesh:

Year:  2009        PMID: 19914445      PMCID: PMC6324931          DOI: 10.1016/j.jpeds.2009.09.001

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  132 in total

1.  Parent and child mealtime behavior in families of children with cystic fibrosis.

Authors:  L J Stark; E Jelalian; S W Powers; M M Mulvihill; L C Opipari; A Bowen; I Harwood; M A Passero; A Lapey; M Light; M F Hovell
Journal:  J Pediatr       Date:  2000-02       Impact factor: 4.406

2.  Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen.

Authors:  A P Feranchak; M K Sontag; J S Wagener; K B Hammond; F J Accurso; R J Sokol
Journal:  J Pediatr       Date:  1999-11       Impact factor: 4.406

3.  Pancreatic elastase 1 in feces of preterm and term infants.

Authors:  K Nissler; I Von Katte; A Huebner; J Henker
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-07       Impact factor: 2.839

4.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener
Journal:  Pediatr Pulmonol       Date:  1999-11

5.  Treatment of vitamin K deficiency in cystic fibrosis: Effectiveness of a daily fat-soluble vitamin combination.

Authors:  D C Wilson; M Rashid; P R Durie; A Tsang; D Kalnins; M Andrew; M Corey; J Shin; E Tullis; P B Pencharz
Journal:  J Pediatr       Date:  2001-06       Impact factor: 4.406

6.  Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.

Authors:  M R Kosorok; L Zeng; S E West; M J Rock; M L Splaingard; A Laxova; C G Green; J Collins; P M Farrell
Journal:  Pediatr Pulmonol       Date:  2001-10

7.  Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients.

Authors:  G Steinkamp; H Demmelmair; I Rühl-Bagheri; H von der Hardt; B Koletzko
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-10       Impact factor: 2.839

8.  Abnormalities in zinc homeostasis in young infants with cystic fibrosis.

Authors:  N F Krebs; J E Westcott; T D Arnold; B M Kluger; F J Accurso; L V Miller; K M Hambidge
Journal:  Pediatr Res       Date:  2000-08       Impact factor: 3.756

9.  Nocturnal oximetry in infants with cystic fibrosis.

Authors:  M P Villa; J Pagani; V Lucidi; S Palamides; R Ronchetti
Journal:  Arch Dis Child       Date:  2001-01       Impact factor: 3.791

10.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

View more
  96 in total

1.  Regional differences in the evolution of lung disease in children with cystic fibrosis.

Authors:  Zhanhai Li; Don B Sanders; Michael J Rock; Michael R Kosorok; Jannette Collins; Christopher G Green; Alan S Brody; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-12-07

2.  Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

Authors:  Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

3.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

4.  New challenges in the diagnosis and management of cystic fibrosis.

Authors:  Hara Levy; Philip M Farrell
Journal:  J Pediatr       Date:  2015-06       Impact factor: 4.406

5.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

6.  Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.

Authors:  Don B Sanders; Zhumin Zhang; Philip M Farrell; HuiChuan J Lai
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

7.  Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).

Authors:  Ian Mitchell; S K Wong; B Paes; M Ruff; C Bjornson; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-04       Impact factor: 3.267

8.  Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.

Authors:  Daniel H Leung; Sonya L Heltshe; Drucy Borowitz; Daniel Gelfond; Margaret Kloster; James E Heubi; Michael Stalvey; Bonnie W Ramsey
Journal:  JAMA Pediatr       Date:  2017-06-01       Impact factor: 16.193

Review 9.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

10.  Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis.

Authors:  Michelle E Condren; Marquita D Bradshaw
Journal:  J Pediatr Pharmacol Ther       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.